Resultado de búsqueda
17 de mar. de 2019 · We conducted the AUGUSTUS trial (a two-by-two factorial, randomized, controlled clinical trial) to assess the safety and efficacy of standard-dose apixaban as compared with a vitamin K...
29 de mar. de 2020 · Among patients with atrial fibrillation with recent ACS or PCI in the AUGUSTUS trial, adding apixaban to a P2Y 12 inhibitor resulted in lower bleeding compared with VKA with a lower rate of death or rehospitalization.
19 de ene. de 2021 · An open-label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial.
18 de abr. de 2019 · Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an ...
2 de jul. de 2019 · AUGUSTUS is the first trial with a two-by-two factorial design in patients with atrial fibrillation (AF) on combined antithrombotic therapy after an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), respectively. 1 Thereby, it allows the independent evaluation of the effects of prescribing apixaban ...
15 de abr. de 2019 · La triple terapia con doble antiagregación y anticoagulación asocia un aumento importante del riesgo de sangrado. El estudio AUGUSTUS es un estudio prospectivo, multicéntrico y aleatorizado con un diseño factorial 2 x 2, que compara el tratamiento con apixabán frente a antivitamina K, y aspirina frente a placebo, en pacientes ...
1 de ago. de 2020 · We aimed at defining the efficacy and safety of double antithrombotic therapy with single antiplatelet therapy (SAPT) plus a non–vitamin K antagonist oral anticoagulant (NOAC) against triple antithrombotic therapy with dual antiplatelet therapy (DAPT) added to a vitamin K antagonist (VKA), illustrating the pooled cumulative distribution of event...
